Robert W. Baird Boosts Agilent Technologies (NYSE:A) Price Target to $156.00

Agilent Technologies (NYSE:A) had its price target increased by equities researchers at Robert W. Baird from $155.00 to $156.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the medical research company’s stock. Robert W. Baird’s price objective suggests a potential upside of 35.65% from the stock’s previous close.

A number of other brokerages have also recently issued reports on A. Wells Fargo & Company reduced their price objective on shares of Agilent Technologies from $175.00 to $165.00 and set an “overweight” rating for the company in a research note on Thursday, February 26th. UBS Group dropped their target price on shares of Agilent Technologies from $180.00 to $165.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Wall Street Zen lowered shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Morgan Stanley dropped their target price on shares of Agilent Technologies from $180.00 to $160.00 and set an “overweight” rating for the company in a research report on Tuesday, March 3rd. Finally, TD Cowen dropped their target price on shares of Agilent Technologies from $170.00 to $157.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Agilent Technologies currently has a consensus rating of “Buy” and an average target price of $163.07.

Agilent Technologies Stock Performance

Shares of NYSE A opened at $115.01 on Tuesday. The firm has a fifty day moving average price of $114.84 and a 200-day moving average price of $129.23. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.07 and a quick ratio of 1.59. The stock has a market cap of $32.50 billion, a PE ratio of 25.39, a price-to-earnings-growth ratio of 2.42 and a beta of 1.22. Agilent Technologies has a 1 year low of $107.07 and a 1 year high of $160.27.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Wednesday, February 25th. The medical research company reported $1.36 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.37 by ($0.01). The firm had revenue of $1.80 billion during the quarter, compared to analysts’ expectations of $1.81 billion. Agilent Technologies had a return on equity of 24.49% and a net margin of 18.26%.The business’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period last year, the company earned $1.31 earnings per share. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. Equities analysts anticipate that Agilent Technologies will post 5.95 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Agilent Technologies

Several institutional investors have recently bought and sold shares of A. Brighton Jones LLC lifted its position in Agilent Technologies by 6.1% during the fourth quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company’s stock valued at $626,000 after purchasing an additional 270 shares during the last quarter. Jones Financial Companies Lllp lifted its position in Agilent Technologies by 15.9% during the first quarter. Jones Financial Companies Lllp now owns 5,610 shares of the medical research company’s stock valued at $602,000 after purchasing an additional 769 shares during the last quarter. Geneos Wealth Management Inc. lifted its position in Agilent Technologies by 54.8% during the first quarter. Geneos Wealth Management Inc. now owns 599 shares of the medical research company’s stock valued at $70,000 after purchasing an additional 212 shares during the last quarter. Acadian Asset Management LLC lifted its position in Agilent Technologies by 16.5% during the first quarter. Acadian Asset Management LLC now owns 5,352 shares of the medical research company’s stock valued at $625,000 after purchasing an additional 758 shares during the last quarter. Finally, Sivia Capital Partners LLC bought a new position in Agilent Technologies during the second quarter valued at $273,000.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.